Analyst Joel Beatty of Robert W. Baird maintained a Buy rating on Immutep ( IMMP – Research Report ), with a price target of $7.00. Joel Beatty assigned a Buy rating to Immutep's stock based on several compelling factors. One of the key elements that influenced this decision is the promising data from the TACTI-002 study on the use of eftilagimod alpha (efti) in first-line NSCLC. The study showed impressive results, with the median overall survival rate for patients treated with efti plus pembrolizumab extending to 35.5 months, a significant improvement from the previous 25 months, indicating that this treatment could be more effective than common regimens. Furthermore, Beatty was also encouraged by the data from the INSIGHT-003 trial, which showed that a triple combination therapy involving efti also yielded positive results. In addition to these, Immutep has shared its plans for a Phase 3 program, which Beatty finds promising.